NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 137
- 试验地点
- 15
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
The main objective of the trial is to document the efficacy of NGR-hTNF administered as maintenance treatment at 0.8 µg/m2 weekly in advanced malignant pleural mesothelioma
详细描述
First-line treatment of advanced malignant pleural mesothelioma (MPM) is based on six cycles of a pemetrexed-based chemotherapy, with a median progression-free survival (PFS) of approximately 6 months.However, the median time from completion of first-line treatment to initiation of second-line therapy is approximately 3 months. Recent experiences in non-small cell lung cancer patients have shown that a maintenance treatment given immediately after first-line treatment regimens can improve PFS and survival. Considering the toxicity profile of NGR-hTNF characterized by mild-to-moderate constitutional symptoms registered in a phase II trial in previously treated MPM patients, as well as the disease control observed in about half of the patients and maintained for more than four months and more than nine months in the triweekly and weekly cohorts, respectively, seems justified to compare in a randomized phase II trial the time-related efficacy of NGR-hTNF against placebo in advanced MPM patients who did not progress after six cycles of a standard pemetrexed-based treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatoid, mixed, or unknown
- •Patients with non-progressive disease after six cycles of first-line, pemetrexed-based regimen administered for advanced or metastatic disease
- •ECOG Performance Status 0 - 1
- •Life expectancy of ≥ 12 weeks
- •Adequate baseline bone marrow, hepatic and renal function, defined as follows:
- •Neutrophils ≥ 1.5 x 109/L; platelets ≥ 100 x109/L; hemoglobin ≥ 9 g/dL
- •Bilirubin ≤ 1.5 x ULN
- •AST and/or ALT ≤ 2.5 x ULN in absence of liver metastasis or ≤ 5 x ULN in presence of liver metastasis
- •Serum creatinine < 1.5 x ULN
- •Measurable or non-measurable disease according to malignant pleural mesothelioma-modified RECIST criteria
- •Patients may have had prior therapy providing the following conditions are met:
- •Surgery: wash-out period of 14 days
- •Radiation therapy: wash-out period of 28 days
- •Chemotherapy: wash-out period of 21 days
- •Patients must give written informed consent to participate in the study
排除标准
- •Patients must not receive any other investigational agents while on study
- •Patients with myocardial infarction within the last six months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
- •Uncontrolled hypertension
- •QTc interval (congenital or acquired) > 450 ms
- •History or evidence upon physical examination of Central Nervous System disease unless adequately treated
- •Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
- •Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
- •Pregnancy or lactation.
研究组 & 干预措施
Arm A: NGR-hTNF + Best Supportive Care
NGR-hTNF + Best Supportive Care
干预措施: NGR-hTNF (Drug)
Arm A: NGR-hTNF + Best Supportive Care
NGR-hTNF + Best Supportive Care
干预措施: Best Supportive Care (Other)
Arm B: Placebo + Best Supportive Care
Placebo + Best Supportive Care
干预措施: Placebo (Drug)
Arm B: Placebo + Best Supportive Care
Placebo + Best Supportive Care
干预措施: Best Supportive Care (Other)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: every 6 weeks
Defined as the time from the date of randomization until disease progression, or death
次要结局
- Overall survival (OS)(every 6-12 weeks)
- Tumor response(every 6 weeks)
- Safety and Toxicity according to NCI-CTCAE criteria(version 4.03)(during the study)
- Quality of life assessment by using a questionnaire according to Lung Cancer Symptom Scale (LCSS)(From date of randomization until the end of treatment, assessed every 6 weeks)